Oruka Therapeutics, Inc. (ORKA)

Oruka Therapeutics, Inc. is trading at $112.51, down 0.13% on the session. The 50 day average sits at $86.82 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 74.2, which reads as overbought, and MACD is bullish crossover. Volume is above average.

The nearest support is around $95.50 with resistance near $111.37, so that band frames the current range. Average daily movement is roughly $5.43, or about 4.8% of the share price, which is what any stop placement has to allow for. The overall health score of 67 out of 100 combines a trend score of 75, momentum of 78 and a risk score of 38.

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.